Fielder Capital Group LLC Invests $66,000 in Neuronetics, Inc. (NASDAQ:STIM)

Fielder Capital Group LLC bought a new stake in Neuronetics, Inc. (NASDAQ:STIM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 22,797 shares of the company’s stock, valued at approximately $66,000. Fielder Capital Group LLC owned approximately 0.08% of Neuronetics at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new stake in shares of Neuronetics during the 4th quarter valued at $87,000. David J Yvars Group lifted its stake in Neuronetics by 108.1% during the fourth quarter. David J Yvars Group now owns 74,930 shares of the company’s stock worth $217,000 after purchasing an additional 38,930 shares during the last quarter. First Eagle Investment Management LLC lifted its stake in Neuronetics by 33.8% during the third quarter. First Eagle Investment Management LLC now owns 776,009 shares of the company’s stock worth $1,048,000 after purchasing an additional 195,834 shares during the last quarter. Kent Lake Capital LLC boosted its holdings in shares of Neuronetics by 229.8% in the 3rd quarter. Kent Lake Capital LLC now owns 2,329,287 shares of the company’s stock worth $3,145,000 after purchasing an additional 1,622,938 shares in the last quarter. Finally, Cannell Capital LLC increased its position in shares of Neuronetics by 2.4% during the 3rd quarter. Cannell Capital LLC now owns 2,833,982 shares of the company’s stock valued at $3,826,000 after purchasing an additional 65,240 shares during the last quarter. 53.59% of the stock is currently owned by institutional investors.

Insider Activity at Neuronetics

In other news, EVP William Andrew Macan sold 15,621 shares of the stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $3.38, for a total transaction of $52,798.98. Following the completion of the sale, the executive vice president now directly owns 417,736 shares in the company, valued at $1,411,947.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Stephen Furlong sold 14,710 shares of Neuronetics stock in a transaction on Friday, February 9th. The shares were sold at an average price of $3.51, for a total value of $51,632.10. Following the sale, the chief financial officer now owns 509,033 shares in the company, valued at $1,786,705.83. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP William Andrew Macan sold 15,621 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $3.38, for a total transaction of $52,798.98. Following the completion of the sale, the executive vice president now directly owns 417,736 shares of the company’s stock, valued at $1,411,947.68. The disclosure for this sale can be found here. Insiders sold 150,279 shares of company stock worth $489,167 in the last three months. 9.80% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $8.00 target price (up previously from $7.00) on shares of Neuronetics in a research report on Wednesday, March 6th. William Blair restated a “market perform” rating on shares of Neuronetics in a report on Tuesday, March 26th.

Neuronetics Trading Down 1.6 %

Shares of NASDAQ:STIM traded down $0.06 on Monday, reaching $3.75. 146,169 shares of the company traded hands, compared to its average volume of 172,055. The stock has a market capitalization of $112.43 million, a P/E ratio of -3.35 and a beta of 2.50. The business’s 50-day simple moving average is $3.96 and its 200 day simple moving average is $2.93. The company has a current ratio of 4.73, a quick ratio of 4.33 and a debt-to-equity ratio of 1.73. Neuronetics, Inc. has a 52 week low of $1.03 and a 52 week high of $5.07.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.07. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. The business had revenue of $20.31 million for the quarter, compared to analyst estimates of $19.73 million. During the same period last year, the company earned ($0.30) EPS. As a group, equities analysts anticipate that Neuronetics, Inc. will post -0.92 EPS for the current fiscal year.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.